Faculty Bibliography

Try a new search

Format these results:

Searched for:

in-biosketch:true

person:adlerl01

Total Results:

260

Psychopharmacology bulletin. 1996:32(3):406-406.DOI:

Prescribing characteristics of newer generation antidepressants in a veterans affairs psychiatry clinic [Meeting Abstract]

Adler, LA; Vanderburg, D; Resnick, S; Rotrosen, J
ISI:A1996VQ76300026
ISSN: 0048-5764
CID: 52725
Psychopharmacology bulletin. 1996:32(3):436-436.DOI:

Interrater reliability issues in multicenter trials .2. Statistical procedures used in VA Cooperative Study #394 [Meeting Abstract]

Edson, R; Lavori, P; Tracy, K; Adler, LA; Rotrosen, J
ISI:A1996VQ76300056
ISSN: 0048-5764
CID: 52729
Psychopharmacology bulletin. 1996:32(3):526-526.DOI:

Interrater reliability issues in multicenter trials .1. Theoretical concepts and operational procedures in VA Cooperative Study #394 [Meeting Abstract]

Tracy, K; Adler, LA; Rotrosen, J; Edson, R; Lavori, P
ISI:A1996VQ76300146
ISSN: 0048-5764
CID: 52731
Biological psychiatry. 1996:39(7):185-185.DOI:

Co-morbidity of attention deficit disorder in adult patients screened for [Meeting Abstract]

Adler, LA; Resnick, S; Rotrosen, J
ISI:A1996UE89300181
ISSN: 0006-3223
CID: 52981
Biological psychiatry. 1996:39(7):421-421.DOI:

An open label trial of venlafaxine in adults with attention deficit disorder [Meeting Abstract]

Adler, LA; Resnick, S; Kunz, M; Devinsky, O
ISI:A1996UE89300407
ISSN: 0006-3223
CID: 52982
Biological psychiatry. 1996:40(8):798-9.DOI: 10.1016/0006-3223(96)00268-5

Nefazodone and akathisia [Case Report]

Eberstein, S; Adler, L A; Angrist, B
PMID: 8894074
ISSN: 0006-3223
CID: 106685
Psychopharmacology bulletin. 1995:31(4):785-8.DOI:

Open-label trial of venlafaxine in adults with attention deficit disorder

Adler LA; Resnick S; Kunz M; Devinsky O
Antidepressants or stimulants are commonly used to treat attention deficit disorder (ADD). We report the results of an open-label trial of the recently marketed antidepressant venlafaxine in 16 adult patients with ADD. Patients were treated with venlafaxine (25 to 225 mg/day) for 8 weeks. Four patients discontinued treatment within the first week because of sedation, agitation, or nausea. In the remaining 12 patients, venlafaxine treatment decreased ADD ratings by almost half
PMID: 8851654
ISSN: 0048-5764
CID: 12816
Psychiatric annals. 1995:25(5):306-310.DOI:

THE IMPORTANCE OF SIDE-EFFECTS IN THE DEVELOPMENT OF NEW ANTIPSYCHOTIC-DRUGS [Meeting Abstract]

ROTROSEN, J; ADLER, L
ISI:A1995QZ34900007
ISSN: 0048-5713
CID: 87295
Biological psychiatry. 1995:37(5):336-7.DOI: 10.1016/0006-3223(94)00158-Y

Paroxetine and akathisia [Case Report]

Adler, L A; Angrist, B M
PMID: 7748986
ISSN: 0006-3223
CID: 106687
Biological psychiatry. 1994:35(9):696-696.DOI:

TRAINING RATERS TO ASSESS NEUROLEPTIC-INDUCED AKATHISIA USING STANDARDIZED VIDEOTAPES [Meeting Abstract]

ADLER, LA; NIERENBERA, AA; FAVA, M; HANNIBAL, J; ROTROSEN, J
ISI:A1994NJ17200291
ISSN: 0006-3223
CID: 52474